Nova Patents
PL368205A1

Adenosine a3 receptor agonists

Abstract

Disclosed are novel compounds that are A3 adenosine receptor agonists, useful for treating various disease states, including cancer, cardiac ischemia, leukopenia, and neutropennia.

Term

Term ended

Projected expiry passed 6 August 2022, 4.1 years ago.

  1. Priority
  2. Filed
  3. Published
  4. Projected expiry
  5. Today

33 members in 20 offices

This recordMember, by publication datePriority claim10 more offices are in the list below

Priority claims4

Priority claims
DocumentOfficeKindDate
31106901United States of AmericaP
31106901United States of AmericaP
0160311069–––
US20010311069P–––

Members33

Family members, oldest first
DocumentOfficeKind
CA2456744A1CanadaA1
WO03014137A1World Intellectual Property Organization (WIPO)A1
AU2002327426A2AustraliaA2
US2003078232A1United States of AmericaA1
KR20040023733ARepublic of KoreaA
NO20040969LNorwayL
EP1414837A1European Patent Office (EPO)A1
US2004116376A1United States of AmericaA1
IL160231D0IsraelD0
ZA200401000BSouth AfricaB
CN1538972AChinaA
HU0401437A2HungaryA2
JP2005501842AJapanA
PL368205A1This recordPolandA1
MXPA04001185AMexicoA
RU2004106635ARussian FederationA
NZ530976ANew ZealandA
EP1414837B1European Patent Office (EPO)B1
DK1414837T3DenmarkT3
AT307136TAustriaT
ES2247371T3SpainT3
DE60206775D1GermanyD1
CN1244589CChinaC
DE60206775T2GermanyT2
RU2298557C2Russian FederationC2
HU0401437A3HungaryA3
AU2002327426B2AustraliaB2
US7262176B2United States of AmericaB2
AU2002327426C1AustraliaC1
KR100923888B1Republic of KoreaB1
JP4357960B2JapanB2
NO327997B1NorwayB1
IL160231AIsraelA